BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910 by Jen Brogan | Jun 2, 2023 | News | 0 BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development Read More
Tiziana submits IND for Foralumab oral formulation in NASH by Anna Smith | Mar 26, 2019 | News | 0 Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab. Read More